Effects of Ampyra (Dalfampridine) on Multi-Dimensional Aspects of Gait and Dexterity in Multiple Sclerosis among Timed Walk Responders and Non-Responders: STUDY

Image source: YOUTUBE


Dalfampridine extended release 10 mg tablets (D-ER) have demonstrated improvement in walking for ambulatory persons with multiple sclerosis (pwMS), termed “responders.”

This study examined the extent additional aspects of gait and dexterity change for patients prescribed D-ER.

Over 14-weeks, walking endurance, dynamic gait, self-report walking ability andfine and gross dexterity were examined in pwMS prescribed D-ER as a part of routine clinical care.

The final results (n = 39) validate that a subset of pwMS improve walking speed (Time 25-Foot Walk Test, p < 0.0001). Significant improvements in gait and dexterity were observed even among participants who did not improve walking speed. Improvements were evident in gait and dexterity domains including Six Minute Walk Test, p = 0.007, Six-Spot Step Test, p < 0.0001, Multiple Sclerosis Walking Scale-12, p < 0.0001, Nine Hole Peg Test, p < 0.0001 dominant and non-dominant sides, and Box and Blocks Test, p = 0.005 and 0.002, dominant and non-dominant sides, respectively.

These findings suggest that D-ER may be a potential treatment for gait impairments, beyond walking speed and dexterity in pwMS. Further investigation regarding D-ER response is warranted.

Story Source: The above story is based on materials provided by SCIENCEDIRECT
Note: Materials may be edited for content and length
Click here to read original article